Tags

Type your tag names separated by a space and hit enter

Sildenafil citrate improves fetal outcomes in pregnant, L-NAME treated, Sprague-Dawley rats.
Eur J Obstet Gynecol Reprod Biol. 2010 Mar; 149(1):22-6.EJ

Abstract

OBJECTIVES

This study aimed to investigate the effects of sildenafil citrate on various fetal and physiological parameters, including fetal mortality, number of pups, placental weights and micro-albuminuria in pregnant, L-NAME treated Sprague-Dawley rats.

STUDY DESIGN

Twenty-four pregnant female Sprague-Dawley rats were divided into 3 groups (n=8). In the L-NAME treated group (PRE), l-NAME (0.3 g/l, drinking water) was used to induce pre-eclampsia-like symptoms on day 1 of the experiment. The experimental group (SCT) also received L-NAME (0.3 g/l, drinking water) on day 1 of the experiment. However, sildenafil citrate (10 mg/kg, s.c., daily) was administered as the test compound from day 7 until day 19. The experimental control (CON) did not receive either L-NAME or sildenafil citrate. L-NAME administration was discontinued in both the PRE and the SCT groups on day 19 of the experiment and the animals were given access to normal drinking water ad libitum. All the animals were sacrificed on day 20, at which time a laparotomy was performed and the various fetal parameters measured. On day 0 and day 20, blood pressure measurements were recorded non-invasively and protein estimations in 24h urine samples were conducted.

RESULTS

Sildenafil citrate decreased fetal mortality and protein excretion and further demonstrated a trend toward increasing birth and placental weights in pregnant, L-NAME treated, Sprague-Dawley rats. In addition, sildenafil citrate administration ameliorated the amplification of the L-NAME induced hypertension in the SCT group.

CONCLUSION

We speculate that sildenafil citrate by potentiating the effects of nitric oxide in vivo improves uterine artery blood flow resulting in improved fetal outcomes in pregnant, L-NAME treated, Sprague-Dawley rats.

Authors+Show Affiliations

Department of Physiology and Physiological Chemistry, University of KwaZulu-Natal, Durban, South Africa. ramesars@ukzn.ac.zaNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20034724

Citation

Ramesar, S V., et al. "Sildenafil Citrate Improves Fetal Outcomes in Pregnant, L-NAME Treated, Sprague-Dawley Rats." European Journal of Obstetrics, Gynecology, and Reproductive Biology, vol. 149, no. 1, 2010, pp. 22-6.
Ramesar SV, Mackraj I, Gathiram P, et al. Sildenafil citrate improves fetal outcomes in pregnant, L-NAME treated, Sprague-Dawley rats. Eur J Obstet Gynecol Reprod Biol. 2010;149(1):22-6.
Ramesar, S. V., Mackraj, I., Gathiram, P., & Moodley, J. (2010). Sildenafil citrate improves fetal outcomes in pregnant, L-NAME treated, Sprague-Dawley rats. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 149(1), 22-6. https://doi.org/10.1016/j.ejogrb.2009.11.005
Ramesar SV, et al. Sildenafil Citrate Improves Fetal Outcomes in Pregnant, L-NAME Treated, Sprague-Dawley Rats. Eur J Obstet Gynecol Reprod Biol. 2010;149(1):22-6. PubMed PMID: 20034724.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Sildenafil citrate improves fetal outcomes in pregnant, L-NAME treated, Sprague-Dawley rats. AU - Ramesar,S V, AU - Mackraj,I, AU - Gathiram,P, AU - Moodley,J, Y1 - 2010/01/19/ PY - 2009/04/28/received PY - 2009/09/14/revised PY - 2009/11/13/accepted PY - 2009/12/26/entrez PY - 2009/12/26/pubmed PY - 2010/5/4/medline SP - 22 EP - 6 JF - European journal of obstetrics, gynecology, and reproductive biology JO - Eur J Obstet Gynecol Reprod Biol VL - 149 IS - 1 N2 - OBJECTIVES: This study aimed to investigate the effects of sildenafil citrate on various fetal and physiological parameters, including fetal mortality, number of pups, placental weights and micro-albuminuria in pregnant, L-NAME treated Sprague-Dawley rats. STUDY DESIGN: Twenty-four pregnant female Sprague-Dawley rats were divided into 3 groups (n=8). In the L-NAME treated group (PRE), l-NAME (0.3 g/l, drinking water) was used to induce pre-eclampsia-like symptoms on day 1 of the experiment. The experimental group (SCT) also received L-NAME (0.3 g/l, drinking water) on day 1 of the experiment. However, sildenafil citrate (10 mg/kg, s.c., daily) was administered as the test compound from day 7 until day 19. The experimental control (CON) did not receive either L-NAME or sildenafil citrate. L-NAME administration was discontinued in both the PRE and the SCT groups on day 19 of the experiment and the animals were given access to normal drinking water ad libitum. All the animals were sacrificed on day 20, at which time a laparotomy was performed and the various fetal parameters measured. On day 0 and day 20, blood pressure measurements were recorded non-invasively and protein estimations in 24h urine samples were conducted. RESULTS: Sildenafil citrate decreased fetal mortality and protein excretion and further demonstrated a trend toward increasing birth and placental weights in pregnant, L-NAME treated, Sprague-Dawley rats. In addition, sildenafil citrate administration ameliorated the amplification of the L-NAME induced hypertension in the SCT group. CONCLUSION: We speculate that sildenafil citrate by potentiating the effects of nitric oxide in vivo improves uterine artery blood flow resulting in improved fetal outcomes in pregnant, L-NAME treated, Sprague-Dawley rats. SN - 1872-7654 UR - https://www.unboundmedicine.com/medline/citation/20034724/Sildenafil_citrate_improves_fetal_outcomes_in_pregnant_L_NAME_treated_Sprague_Dawley_rats_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0301-2115(09)00680-0 DB - PRIME DP - Unbound Medicine ER -